Lineage Cell Therapeutics, Inc. (LCTX)
Develops lab-grown cell treatments for blindness, spinal cord injuries, and hearing loss
$1.07+0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+8.1%
The outlook
LCTX is trading near its 52-week lows, well below its key moving averages, though analysts are strongly bullish with an average price target about 414% above the current price. The stock's trend remains weak despite the optimistic consensus rating. Coverage is solid at six analysts, suggesting meaningful research attention.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 6 analysts
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +414% vs current price
Analyst price target
~12-month · 6 analysts$5.50average target+414.0% vs now
Now $1.07
Low $3.00High $9.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$266.7M
52-wk high
$2.09
52-wk low
$0.95
50-day avg
$1.24
200-day avg
$1.56
Trailing P/E
—